Popular Keywords

Breast cancer

Cancer

Cancer biology

Cancer diagnosis and molecular pathology

Cancer prevention

Cancer survivors

Proposal for Radiotherapy Dose Constraint Predicting Uterus Fertility Sparing: A Successful Pregnancy Case Report Following Curative Chemoradiotherapy for Rectal.

Correspondence to Author: Lohynska Radka 

Department of Oncology, First Faculty of Medicine of Charles University.

ABSTRACT

Curative sphincter sparing radiation is a treatment option for early rectal cancer patients who do not qualify for drastic surgery. There have been several treatments explored to preserve fertility in young patients. Radiation dose to the ovaries and uterus determines pregnancy rates following pelvic radiotherapy. In 2003, a 32-year-old female had 58.6 Gy of irradiation for anorectal adenocarcinoma T2 N0 M0, followed by curative chemoradiotherapy. The overall average dose to the uterus was 16 Gy, and 35 Gy To the uterine cervix. Prior to receiving radiotherapy, the patient underwent laparoscopic lateral cranial ovarian transposition. Despite unsuccessful spontaneous pregnancy, the patient had in vitro fertilization with donor eggs and had twins 10 years after radiotherapy treatment. At 38 weeks gestation, she successfully delivered two healthy infants weighing 2420g and 2220g via caesarean surgery we provide a case of full-term twin delivery following curative radiation for anorectal cancer. This is the first account of a successful pregnancy after sphincter sparing curative pelvic surgery. Radiation to total dose: 58.6 Gy. The average dose to the uterus was 16 Gy, while the uterine cervix received 35 Gy. To accommodate treatment planning constraints, we accepted doses that maintained uterine function throughout pregnancy following pelvic radiation.

Citation:

Lohynska Radka. Proposal for Radiotherapy Dose Constraint Predicting Uterus Fertility Sparing: A Successful Pregnancy Case Report Following Curative Chemoradiotherapy for Rectal. The European Journal of Cancer 2024.

Journal Info

  • Journal Name: The European Journal of Cancer
  • Impact Factor: 2.0
  • ISSN: 3064-6731
  • DOI: 10.52338/tejoc
  • Short Name: TEJOC
  • Acceptance rate: 55%
  • Volume: 7 (2024)
  • Submission to acceptance: 25 days
  • Acceptance to publication: 10 days
  • Crossref indexed journal
  • Publons indexed journal
  • Pubmed-indexed journal
  • International Scientific Indexing (ISI)-indexed journal
  • Eurasian Scientific Journal Index (ESJI) index journal
  • Semantic Scholar indexed journal
  • Cosmos indexed journal

OUR PUBLICATION BENEFITS

  • International Reach
  • Peer Review
  • Rapid Publication
  • Open Access
  • High Visibility